Update on Autolus proposed NASDAQ IPO

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

 Arix Bioscience plc

Update on Autolus proposed initial public offering in the United States

LONDON, 8 June 2018

Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its largest Group Business holding Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”) has filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share.

The registration statement discloses an indicative pricing range for the proposed offering of U.S.$15.00 – U.S.$17.00 per ADS. This would represent an increase in value of Arix’s current shareholding in Autolus (compared to the £20.1 million 2018 sterling holding value) of £10.5 – £14.6 million. The proposed maximum aggregate offering amount specified in the filing is U.S.$125.0 million, which assumes that the offering price is at the midpoint of the indicative pricing range and does not include the underwriters’ option to purchase additional ADSs.

Arix has indicated an interest in purchasing ADSs in the offering, subject to agreement with the underwriters.

The registration statement can be accessed through the SEC’s EDGAR database.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at [phone] or by email at [e-mail]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at + 1 877 547 6340, or by email at [e-mail]. For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant EU member state) and will not have been reviewed by any competent authority in any EU member state.

ENDS

Enquiries

For more information on Arix, please contact:

Investor contact

Arix Bioscience plc

Charlotte Parry, Investor Relations Manager

[phone]

[e-mail]

Media Contact

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

[phone]

[e-mail]

US Investor and Media contact

Burns McClellan

Lisa Burns, John Grimaldi, Bill Slattery Jr.

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.]

About Autolus

Autolus is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.